Bicyclic peptide ligand aiming at GPC3, pharmaceutical composition and application of bicyclic peptide ligand

By screening high-affinity bicyclic peptide ligands using phage display technology, the problems of large molecular weight, poor penetration, high cost, and high immunogenicity of existing GPC3 targeting agents in HCC treatment have been solved. This enables highly efficient and specific recognition and targeting of GPC3 protein, making it suitable for tumor diagnosis and treatment.

CN121949467APending Publication Date: 2026-05-01BEIJING TAI RUI HUANYU TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202512030358.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-30
Publication Date
2026-05-01

AI Technical Summary

Technical Problem

Existing GPC3-targeting agents, such as targeted antibodies and CAR-T cell therapy, have problems in treating hepatocellular carcinoma (HCC) such as large molecular weight, poor tumor penetration, high production cost, and high immunogenicity, making it difficult to achieve large-scale application.

Method used

We developed bicyclic peptide ligands targeting GPC3, using phage display and panning techniques to screen for bicyclic peptide ligands with binding forces ranging from micromolar to nanomolar. These ligands were then used to bind to the GPC3 protein with high affinity and specificity, and their stability and bioactivity were improved through chemical modification.

Benefits of technology

It achieves efficient and specific recognition and targeting of GPC3 protein, reduces immunogenicity, expands the scope of application, and is suitable for the diagnosis and treatment of tumors with high GPC3 expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to a bicyclic peptide ligand aiming at GPC3, a pharmaceutical composition and application of the bicyclic peptide ligand. The bicyclic peptide ligand provided by the invention has high binding affinity and specificity with the GPC3 protein, and can effectively realize recognition and targeting of the GPC3 protein. Compared with an antibody inhibitor, the bicyclic peptide inhibitor has significantly lower immunogenicity and can effectively reduce side effects. The bicyclic peptide ligand provided by the invention can be used as a tool for researching the action of the GPC3 protein in the physiological process, can be used as a candidate targeting molecule of an anti-tumor drug, and is used for the scenes of early diagnosis, prevention, treatment and the like of HCC and other tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Bicyclic peptide ligands, pharmaceutical compositions and their applications targeting GPC3 Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to bicyclic peptide ligands for GPC3, pharmaceutical compositions, and their applications. Background Technology

[0002] Liver cancer is the second leading cause of cancer death worldwide, accounting for approximately 8.2% of all deaths, and hepatocellular carcinoma (HCC) is the most common type of liver cancer. Only about 40% of HCC cases are diagnosed at an early stage, resulting in unsatisfactory clinical treatment outcomes. Current treatment options for liver cancer include surgical resection, liver transplantation, and systemic chemotherapy. These methods have drawbacks such as high surgical difficulty, insufficient organ supply, and significant side effects. Immunotherapy is another powerful strategy for treating cancer. Although the anti-programmed cell death protein 1 (PD-1) inhibitors nivolumab and pembrolizumab, and the anti-CTLA-4 inhibitors simumab and ipilimumab have shown good anti-tumor activity in HCC, the options for effective systemic treatment of HCC remain limited, with a five-year survival rate of only 18%.

[0003] In recent years, phosphatidylinositol proteoglycan-3 (GPC3) has been discovered to be a heparan sulfate proteoglycan anchored to the cell membrane via glycosylphosphatidylinositol and is involved in multiple processes such as cell growth, differentiation, and migration. In particular, GPC3 is specifically upregulated in hepatocellular carcinoma (HCC), but is rarely expressed or not expressed in normal liver tissue. This makes it a potential diagnostic and therapeutic target for HCC, and developing ligands targeting GPC3 will contribute to the early diagnosis and targeted therapy of HCC.

[0004] Existing GPC3 targeting agents include targeted antibodies, peptide drugs, and CAR-T / NK cells. Reported targeted antibodies include the recombinant monoclonal antibody GC33 targeting the C-terminus of GPC3, 32A9 targeting the middle region of GPC3, and the nanobody HN3 recognizing the intact GPC3 molecule. These antibodies, used alone, have not shown good anti-tumor activity. However, when combined with other antibodies (anti-CD3 monoclonal antibodies, anti-CD47 monoclonal antibodies, etc.) to form bispecific antibodies or conjugated with immunotoxins, they have been shown to achieve effective tumor regression and improve survival rates. However, antibody drugs have large molecular weights and poor tumor penetration; CAR-T cell therapy involves complex humanization, high production costs, and high immunogenicity, easily triggering an immune storm. Therefore, these approaches remain difficult to scale up for application.

[0005] Peptide molecules, with molecular weights between 2 and 5 kDa, possess advantages such as good tissue distribution and high chemical accessibility, while also exhibiting certain biological activity and targeting capabilities. In recent years, the development of peptide ligands with high target affinity to replace monoclonal antibodies in exerting biological activity has received increasing attention. Meanwhile, peptide cyclization is an important technique in peptide drug development. The cyclic structure improves overall structural rigidity and chemical stability, while reducing the recognition and cleavage of amino acid sequences by proteases, thus enhancing resistance to enzymatic degradation. Due to its higher stability and resistance to enzymatic degradation, cyclized peptides can maintain effective concentrations in vivo for longer periods, thereby reducing the frequency of dosing.

[0006] Phage display and panning is an effective method for high-throughput screening of peptide ligands targeting proteins. It utilizes proteins or peptides displayed on the surface of phages as recognition molecules to achieve highly selective binding to specific targets. This technology has been widely applied not only in basic research fields such as biology and pharmacology, but also shows broad application prospects in the development of targeted drugs, diagnostic reagents, and biosensors. Therefore, using phage display and panning for rapid and efficient screening of bicyclic peptides is a powerful tool for the development of bicyclic peptide ligands. Summary of the Invention

[0007] This invention provides bicyclic peptide ligands for GPC3, pharmaceutical compositions, and their applications.

[0008] Specifically, the present invention provides the following technical solutions.

[0009] In a first aspect, the present invention provides a bicyclic peptide ligand for GPC3, the bicyclic peptide ligand having an amino acid sequence or a variant sequence shown in any of SEQ ID NO: 1-4; wherein the variant sequence is a sequence generated by a mutation of at least one amino acid.

[0010] The amino acid sequences shown in SEQ ID NO:1-4 above are shown in Table 1.

[0011] Table 1

[0012] Variant sequences that retain GPC3 binding activity and are capable of forming two ring structures, obtained by mutating at least one amino acid based on the amino acid sequences shown in SEQ ID NO:1-4, are also within the scope of protection of this invention.

[0013] Preferably, the variant sequence is a sequence generated by mutating 1 to 5 amino acids based on any of the amino acid sequences shown in SEQ ID NO:1-4. More preferably, it is a variant sequence with a single amino acid or a double amino acid mutation.

[0014] In some embodiments of the present invention, the amino acid sequence of the bicyclic peptide ligand targeting GPC3 is as shown in any one of SEQ ID NO: 1-4.

[0015] This invention utilizes bicyclic peptide phage display libraries to screen and obtain bicyclic peptides with low to nanomolar binding affinity to GPC3. These bicyclic peptide ligands can bind to GPC3 efficiently and specifically, and can be used as ligands, drugs, and drug development precursors targeting GPC3 protein.

[0016] The structure of the bicyclic peptide ligand for GPC3 described above contains two cyclic structures, which are formed by disulfide bonds.

[0017] Preferably, the cysteine ​​residues in the bicyclic peptide ligand form (Cys2-Cys16 / Cys4-Cys10) and / or (Cys2-Cys10 / Cys4-Cys16) bicyclic peptides via disulfide bonds.

[0018] In some embodiments of the present invention, the bicyclic peptide ligand is formed by natural cyclization, wherein both Cys2-Cys16 / Cys4-Cys10 and Cys2-Cys10 / Cys4-Cys16 cyclization modes are present simultaneously.

[0019] Preferably, the affinity constant K between the bicyclic peptide ligand and GPC3 is... D Less than or equal to 1.5µM. More preferably less than or equal to 1.21µM.

[0020] The bicyclic peptide ligand for GPC3 provided by this invention exhibits high affinity for GPC3, enabling efficient and specific binding to GPC3. Based on its performance, this invention provides the following applications of the bicyclic peptide ligand.

[0021] The GPC3 protein described in this invention is the human GPC3 protein, and its amino acid sequence can be obtained from publicly available databases.

[0022] Secondly, this invention provides the application of the bicyclic peptide ligands for GPC3 described above in the construction of drug screening models for GPC3 detection or targeting GPC3.

[0023] The bicyclic peptide ligand targeting GPC3 can be used to detect GPC3 by binding to GPC3. Preferably, when used for GPC3 detection, the bicyclic peptide ligand targeting GPC3 can be coupled to a detectable label such as a fluorescent dye (e.g., FITC) or a radionuclide.

[0024] Thirdly, the present invention provides the application of the above-described bicyclic peptide ligand for GPC3 in the preparation of diagnostic or typing reagents for tumors with high GPC3 expression.

[0025] Fourthly, the present invention provides the use of the above-described bicyclic peptide ligand targeting GPC3 in the preparation of a drug for the prevention or treatment of tumors with high GPC3 expression.

[0026] The GPC3-overexpressing tumors mentioned above refer to tumor tissues where GPC3 is specifically upregulated, but rarely or not expressed in normal tissues. Hepatocellular carcinoma is the preferred candidate.

[0027] Fifthly, the present invention provides a pharmaceutical composition comprising the bicyclic peptide ligand targeting GPC3 as an active ingredient and a pharmaceutical carrier.

[0028] The drug carrier can be any carrier permitted in the pharmaceutical field.

[0029] Preferably, the carrier comprises a polymer, nanoparticles, or liposomes.

[0030] In a sixth aspect, the present invention provides a diagnostic reagent comprising the bicyclic peptide ligand for GPC3 described above.

[0031] Preferably, in the diagnostic reagent, a bicyclic peptide ligand targeting GPC3 is conjugated to a detectable marker. The detectable marker includes, but is not limited to, fluorescent dyes, radionuclides, etc.

[0032] In a seventh aspect, the present invention provides a method for treating or preventing GPC3-overexpressing tumors, the method comprising administering an effective amount of the bicyclic peptide ligand or pharmaceutical composition of the present invention to a subject in need.

[0033] Eighthly, the present invention also provides a method for screening bicyclic peptide ligands with high affinity for GPC3 protein, comprising the following steps: A. Constructing a phage display library containing multiple bicyclic peptide sequences, wherein the peptides in the library have a primary peptide sequence shown as GCXC(X)5C(X)5C (SEQ ID NO:5), wherein X is any amino acid, C is cysteine, and the cysteines in the -CXC- motif guide sequence in the sequence form (Cys2-Cys16 / Cys4-Cys10) and / or (Cys2-Cys10 / Cys4-Cys16) bicyclic peptides through disulfide bonds; B. Incubating the phage display library with immobilized GPC3 protein to allow the bicyclic peptides displayed by the phages to bind to the GPC3 protein; C. Washing to remove unbound phages; D. Recovering the phages bound to the GPC3 protein by acid hydrolysis, enzymatic digestion, or other methods; E. The recovered phages were infecting E. coli and amplified, and the resulting phage library was sequenced to determine the amino acid sequence of the high-affinity bicyclic peptide ligand.

[0034] According to a specific embodiment of the present invention, the specificity and sensitivity of the screening can be improved by adjusting parameters such as washing conditions and incubation conditions during the screening process.

[0035] The beneficial effects of the present invention include at least the following: The bicyclic peptide ligand for GPC3 provided by the present invention has the following advantages compared with existing targeting agents: (1) High affinity: The polypeptide ligand provided by the present invention has a high binding affinity to GPC3 protein, which can effectively realize the recognition and targeting of GPC3 protein.

[0036] (2) High specificity: The polypeptide ligands provided by the present invention have high specificity for GPC3 protein, which can reduce the impact on non-target proteins.

[0037] (3) Low immunogenicity: Compared with antibody inhibitors, the bicyclic peptide inhibitors provided by this invention have significantly lower immunogenicity, which can effectively reduce side effects.

[0038] (4) Flexible and wide application: The bicyclic peptide of the present invention has a variety of geometric configurations. The ligands can be chemically modified or structurally optimized to improve stability, affinity and bioactivity, so as to adapt to applications in multiple fields such as disease diagnosis and treatment.

[0039] The bicyclic peptide ligands provided by this invention can be used as a tool to study the role of GPC3 protein in physiological processes, and can also serve as candidate target molecules for anti-tumor drugs in the early diagnosis, prevention and treatment of tumors such as HCC. Attached Figure Description

[0040] To more clearly illustrate the technical solutions in this invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0041] The bicyclic peptide ligands provided by this invention were purified by high performance liquid chromatography (HPLC) after synthesis, their synthesis was verified by mass spectrometry (MS), and their binding affinity to GPC3 protein was determined by surface plasmon resonance (SPR).

[0042] Figure 1 shows the HPLC (top) and MS data (bottom) of the bicyclic peptide ligand with the sequence shown in SEQ ID NO:1 of the present invention.

[0043] Figure 2 shows the HPLC (top) and MS data (bottom) of the bicyclic peptide ligand with the sequence shown in SEQ ID NO:2 of the present invention.

[0044] Figure 3 shows the HPLC (top) and MS data (bottom) of the bicyclic peptide ligand with the sequence shown in SEQ ID NO:3 of the present invention.

[0045] Figure 4 shows the HPLC (top) and MS data (bottom) of the bicyclic peptide ligand with the sequence shown in SEQ ID NO:4 of this invention.

[0046] Figure 5 shows the SPR detection results of the bicyclic peptide ligands with sequences as shown in SEQ ID NO:1 and SEQ ID NO:2 of the present invention, where A is the bicyclic peptide ligand with sequence as shown in SEQ ID NO:1 and B is the bicyclic peptide ligand with sequence as shown in SEQ ID NO:2.

[0047] Figure 6 shows the SPR detection results of the bicyclic peptide ligands with sequences as shown in SEQ ID NO:3 and SEQ ID NO:4 of the present invention, where A is the bicyclic peptide ligand with sequence as shown in SEQ ID NO:3 and B is the bicyclic peptide ligand with sequence as shown in SEQ ID NO:4. Detailed Implementation

[0048] In specific embodiments, the present invention adopts the following technical solution: (1) Constructing a random bicyclic peptide library using phage display technology. According to specific embodiments, the bicyclic peptide ligands are obtained by panning the bicyclic peptide library displayed by phage for GPC3 protein. The peptides in the bicyclic peptide library have the primary peptide sequence shown in SEQ ID NO:5, and bicyclic peptides (Cys2-Cys16 / Cys4-Cys10) and / or (Cys2-Cys10 / Cys4-Cys16) are formed by disulfide bonds between cysteine ​​residues in the sequence guided by the -CXC- motif. The above bicyclic peptides are linked to the pIII protein of the phage by TEV restriction enzyme digestion.

[0049] (2) Biotin-labeled GPC3 protein as a target for biopanning: According to the specific implementation method for screening bicyclic peptide libraries, the truncated structure (Gln25-His559) of the GPC3 protein used for screening is linked with biotin and then immobilized on magnetic beads coated with streptavidin or neutral avidin. Magnets are used to achieve the interaction between the regulatory protein and the phage library, or to wash and elute the phage. The screening mainly includes the following steps: a. Incubating the phage display library with the immobilized GPC3 protein to allow the bicyclic peptides displayed by the phage to bind to the GPC3 protein; b. Removing unbound phages through multiple washes; c. Recovering the phages through acid digestion, enzymatic digestion, etc.; d. Amplifying the recovered phages and using them as a new library for a new round of screening.

[0050] (3) Analysis of the bicyclic peptide sequences of the screened positive phage clones. According to the specific implementation method, the positive phage libraries collected after the last round of screening in this invention are subjected to DNA extraction, PCR to amplify the target gene, and high-throughput sequencing library construction. All sequence information of the positive phage library is obtained by high-throughput sequencing. The bicyclic peptides are synthesized, expressed, and purified, and their binding activity to GPC3 is tested.

[0051] By controlling experimental conditions, this invention ensures that the obtained polypeptide ligands are highly specific during the screening process, thereby reducing the impact on non-target proteins.

[0052] According to specific embodiments, this invention synthesized the linear peptide sequence of a bicyclic peptide using a microwave solid-phase synthesizer. During synthesis, different protecting groups were used on the two cysteine ​​pairs, and two bicyclic peptide forms were synthesized through a pair-by-pair deprotection process. Furthermore, this invention determined the affinity constant (K0) between the bicyclic peptide ligand and GPC3 protein using SPR. D The range is between 146 nM and 1.21 µM.

[0053] The present invention will be further described in detail below with reference to specific embodiments. These embodiments are not intended to limit the present invention, but only to illustrate it. Unless otherwise specified, the experimental methods used in the embodiments are generally performed under conventional conditions; unless otherwise specified, the materials and reagents used in the embodiments are commercially available.

[0054] Example 1: Screening for high-affinity bicyclic peptide ligands. In this example, a bicyclic peptide phage display library was co-incubated with human GPC3 protein (in this example, a truncated GPC3 structure (Gln25-His559)). Through 3-4 rounds of "adsorption-elution-amplification" steps, phages with strong binding ability were enriched. Specifically: 1. Phage titer determination (1) Take out TG1 glycerol bacteria stored at -80℃, streak them on 2YT-Tet plates, and incubate them overnight at 37℃.

[0055] (2) Pick a single colony of TG1 with a sterile pipette tip and place it in 2YT-Tet liquid medium. Incubate in a shaker until the logarithmic growth phase.

[0056] (3) The initial phage bicyclic peptide library was serially diluted with 2 YT. The initial phage bicyclic peptide library was constructed by introducing the gene of the random peptide -GCXC(X)5C(X)5C- shown in SEQ ID NO:5 into a phage particle, followed by constructing an independent transformation library in E. coli, and then constructing the initial phage library by phage particle lysis. The bicyclic peptide sequence is linked to the pIII protein in the phage coat protein.

[0057] (4) The library was serially diluted with TG1 bacterial suspension in logarithmic growth phase. The bacteria infected by the phage were spread on 2YT solid medium with ampicillin resistance and cultured overnight. The concentration of the original bicyclic peptide phage display library was calculated.

[0058] 2. Phage display and selection (taking one round of selection as an example) (1) Take streptavidin-coated magnetic beads into centrifuge tubes, wash with TBS buffer, and then resuspend the magnetic beads evenly with TBS buffer.

[0059] (2) Add biotin-labeled target protein to one tube, which is designated as the experimental group. Add an equal amount of TBS buffer to the other tube, which is designated as the control group.

[0060] (3) Place the two centrifuge tubes on a shaker and incubate at room temperature. After incubation, separate the magnetic beads, discard the supernatant, and then wash the magnetic beads in both tubes thoroughly with TBS buffer.

[0061] (4) Add TBS buffer containing BSA protein to each of the two tubes, and then incubate both tubes on a shaker at room temperature. Add the same mixture to the phage library and incubate simultaneously on a shaker at room temperature.

[0062] (5) After the phage library was incubated, it was divided into equal parts and added to the magnetic beads of the experimental group and the control group respectively. The two tubes were then placed on a shaker at room temperature for incubation.

[0063] (6) After incubation, separate the magnetic beads and discard the supernatant. Wash the magnetic beads in the two tubes multiple times with TBST buffer. After washing, wash several more times with TBS buffer.

[0064] (7) Then, Gly-HCl buffer was added to resuspend the two magnetic beads separately. After incubation at room temperature, the magnetic beads were separated and the supernatant was recovered into Tris-HCl buffer to complete the recovery of GPC3 protein high affinity phage.

[0065] (8) A suitable amount of the recovered phage fluid was used for titer determination (the operation steps are the same as those for phage titer determination in step 1). The remaining phage fluid was added to the TG1 bacterial culture in the logarithmic growth phase and cultured overnight in 2YT medium at 37°C.

[0066] (9) Collect the colonies into cryovials and add 30% glycerol to the final volume, then freeze them at -80°C to serve as the phage glycerol library for the next round of screening.

[0067] (10) During amplification, take an appropriate amount of the stored phage glycerol stockpile into 2YT liquid medium, add ampicillin, and culture until the logarithmic growth phase.

[0068] (11) Add an appropriate amount of helper phage M13KO7 to the culture and culture it overnight in 2YT medium with both ampicillin and kanamycin sulfate resistance.

[0069] (12) After centrifuging the culture medium, the phages were precipitated with PEG-NaCl, and then the precipitate was dissolved with 1×PBS buffer to obtain the bicyclic peptide phage display library for the next round of screening, which was then dispensed for use.

[0070] (13) The titer of the bicyclic peptide phage display library used in the next round of screening after amplification was determined by the method described in step 1 for phage titer determination.

[0071] The operations performed in the second to fourth rounds of screening are basically the same as those in the first round. Here are some tips on parameters and methods that need to be adjusted in subsequent rounds of screening: A. The amount of GPC3 protein added should be reduced with each round of screening to provide more stringent screening conditions.

[0072] B. During the screening process, streptavidin-coated magnetic beads and neutral avidin-coated magnetic beads should be used alternately to reduce non-specific adsorption. Neutral avidin-coated magnetic beads should be used in a light-protected manner.

[0073] 3. High-throughput sequencing of phage libraries and determination of bicyclic peptide sequences (1) Extract the corresponding phage library DNA from all bicyclic peptide phage display libraries obtained from screening rounds using a conventional commercial M13 phage DNA extraction kit, and amplify the target gene using PCR.

[0074] (2) The next-generation sequencing of the target gene fragment obtained by PCR (completed by Genewiz Biotechnology Co., Ltd. based on the Illumina platform) was used to translate the obtained nucleotide sequence into the primary amino acid sequence of the corresponding bicyclic peptide. After statistically analyzing the proportion of each sequence, the ligand with high affinity for GPC3 protein can be obtained.

[0075] The amino acid sequences of the ligands with high affinity for GPC3 protein are shown in Table 1.

[0076] 4. Synthesis of High-Affinity Bicyclic Peptide Ligand Sequences of GPC3 Protein All peptides were synthesized using solid-phase peptide synthesis (SPPS). During synthesis, Fmoc-protected amino acids were sequentially linked to the resin to form peptide chains. After synthesis, the N-terminal Fmoc group was deprotected first, followed by the deprotection of the side chain protecting groups of each amino acid. Simultaneously, the peptides were separated from the resin. The peptides underwent natural cyclization, resulting in two cyclization conformations for each bicyclic peptide ligand: Cys2-Cys16 / Cys4-Cys10 and Cys2-Cys10 / Cys4-Cys16. The peptides were purified using HPLC and validated using MS. The HPLC and MS detection results for the four bicyclic peptide ligands shown in SEQ ID NO:1-4 are shown in Figures 1, 2, 3, and 4, respectively.

[0077] Example 2: Protein-peptide binding affinity determination. Surface plasmon resonance (SPR) was used to determine the binding affinity of the bicyclic peptides synthesized in Example 1 (sequences shown in SEQ ID NO: 1-4) to human GPC3 protein (in this example, a truncated GPC3 structure (Gln25-His559)). The experiment was performed using Cytiva Biacore™ 8K and Biacore™ 8K+ systems, and a multi-cycle kinetic analysis method was selected for data acquisition, resulting in multi-cycle sensor maps. The results are shown in Figures 5 and 6. By fitting the binding / dissociation curves of the bicyclic peptides and GPC3 protein, the binding kinetic constant ka and dissociation kinetic constant kd were estimated, and the affinity constant K between the bicyclic peptides and the protein was calculated. D= kd / ka.

[0078] Based on the SPR test results, the affinity constants K of the four bicyclic peptides with amino acid sequences as shown in SEQ ID NO:1-4 to the GPC3 protein are... D As shown in Table 2.

[0079] Table 2

[0080] The results above indicate that the four bicyclic peptide ligands in Table 2 have high binding affinity for GPC3 protein, and can effectively achieve the recognition and targeting of GPC3 protein.

[0081] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A bicyclic peptide ligand targeting GPC3, characterized in that, The bicyclic peptide ligand has any of the amino acid sequences shown in SEQ ID NO:1-4 or variant sequences thereof; wherein the variant sequence is a sequence generated by mutation of at least one amino acid, preferably a sequence generated by mutation of 1 to 5 amino acids.

2. The bicyclic peptide ligand for GPC3 according to claim 1, characterized in that, The structure of the bicyclic peptide ligand includes two cyclic structures, which are formed by disulfide bonds.

3. The bicyclic peptide ligand for GPC3 according to claim 2, characterized in that, The cysteine ​​residues in the bicyclic peptide ligands form (Cys2-Cys16 / Cys4-Cys10) and / or (Cys2-Cys10 / Cys4-Cys16) bicyclic peptides via disulfide bonds.

4. The bicyclic peptide ligand for GPC3 according to any one of claims 1 to 3, characterized in that, The affinity constant K between the bicyclic peptide ligand and GPC3 D Less than or equal to 1.5µM; preferably less than or equal to 1.21µM.

5. The application of the bicyclic peptide ligand for GPC3 as described in any one of claims 1 to 4 in the construction of a drug screening model for GPC3 detection or targeting GPC3.

6. The use of the bicyclic peptide ligand for GPC3 according to any one of claims 1 to 4 in the preparation of diagnostic or typing reagents for tumors with high GPC3 expression.

7. The use of the bicyclic peptide ligand for GPC3 according to any one of claims 1 to 4 in the preparation of a medicament for the prevention or treatment of tumors with high GPC3 expression.

8. The application according to claim 6 or 7, characterized in that, The tumors that highly express GPC3 are hepatocellular carcinomas.

9. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises a bicyclic peptide ligand for GPC3 as described in any one of claims 1 to 4 as an active ingredient and a drug carrier; preferably, the carrier comprises a polymer, nanoparticles or liposomes.

10. A diagnostic reagent, characterized in that, The diagnostic reagent comprises the bicyclic peptide ligand for GPC3 as described in any one of claims 1 to 4.